Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW. Kell WJ, et al. Among authors: burnett ak. Blood. 2003 Dec 15;102(13):4277-83. doi: 10.1182/blood-2003-05-1620. Epub 2003 Aug 21. Blood. 2003. PMID: 12933575 Free article. Clinical Trial.
Impact of karyotype on treatment outcome in acute myeloid leukemia.
Grimwade D, Moorman A, Hills R, Wheatley K, Walker H, Harrison G, Harrison Ch, Goldstone A, Burnett A; NCRI Adult Leukaemia Working Party. Grimwade D, et al. Ann Hematol. 2004;83 Suppl 1:S45-8. doi: 10.1007/s00277-004-0849-8. Ann Hematol. 2004. PMID: 15124668 Review.
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, Selleslag D, Theobald M, Fey MF, Vellenga E, Dugan M, Sonneveld P. van der Holt B, et al. Among authors: burnett ak. Blood. 2005 Oct 15;106(8):2646-54. doi: 10.1182/blood-2005-04-1395. Epub 2005 Jun 30. Blood. 2005. PMID: 15994288 Free article. Clinical Trial.
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC. Gale RE, et al. Among authors: burnett ak. Blood. 2005 Nov 15;106(10):3658-65. doi: 10.1182/blood-2005-03-1323. Epub 2005 Aug 2. Blood. 2005. PMID: 16076872 Free article.
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, Nugent E, Mills KI, Wheatley K, Solomon E, Burnett AK, Linch DC, Grimwade D; NCRI Adult Leukaemia Working Party. Gale RE, et al. Among authors: burnett ak. Blood. 2005 Dec 1;106(12):3768-76. doi: 10.1182/blood-2005-04-1746. Epub 2005 Aug 16. Blood. 2005. PMID: 16105978 Free article.
310 results